Studies Wegovy semaglutide safety in people with obesity or overweight
Follows adults with obesity or overweight who take Wegovy in routine care.
Plain-language title generated from the registry record
Registry title: A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
Key facts
- Where
- Busan, Chungcheongnam-do, Daejeon, Goyang-si, Gyeonggi-do, Seoul, and Yangsan, South KoreaSee the 8 sites
Where in South Korea
- Kosin University Gospel HospitalBusan, South KoreaNo longer taking part
- Yonsei Hanaro ClinicChungcheongnam-do, South KoreaNo longer taking part
- Daejeon Endo Internal Medicine ClinicDaejeon, South KoreaNo longer taking part
- MyongJi HospitalGoyang-si, South KoreaNo longer taking part
- Ajou University HospitalGyeonggi-do, South KoreaNo longer taking part
- Hplus Yangji HospitalSeoul, South KoreaNo longer taking part
- Samsung Medical CenterSeoul, South KoreaNo longer taking part
- Pusan National University Yangsan HospitalYangsan, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07018544
- Record updated
- 12 June 2025
- Original description
This study is conducted to investigate the safety and effectiveness of semaglutide in participants with obesity and overweight in routine clinical practice. Participants will get semaglutide as prescribed by a doctor. This study will last for about 4 years and participants will participate in the study for approximately 26 weeks.Read full original descriptionShow less
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea.
This study is conducted to investigate the safety and effectiveness of semaglutide in participants with obesity and overweight in routine clinical practice. Participants will get semaglutide as prescribed by a doctor. This study will last for about 4 years and participants will participate in the study for approximately 26 weeks.
Inclusion: Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol); The decision to initiate treatment with commercially available semaglutide has been made by the participants and the treating physician before and independently from the decision to include the participant in this study; Male or female adults, age above or equal to 19 years who is scheduled to start treatment with semaglutide based on the clinical judgment of their treating physician as specified in the Korean-prescribing Information (approved label in Korea) at the time of signing informed consent.
Exclusion: Participants who are or have previously been on semaglutide therapy before enrollment; Previous participation in this study. Participation is defined as having given informed consent in this study; Known or suspected hypersensitivity to the active substance or any of the excipients of semaglutide; Female participant who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice); Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.